RLAY vs RXRX
RLAY and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RLAYRelay Therapeutics, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $4.06B | $1.81B |
| P/S | 264.2x | 24.2x |
| Revenue growth (YoY) | 53.4% | 26.9% |
| Earnings growth (YoY) | 18.1% | -39.1% |
| EBIT margin | -1971.6% | -867.9% |
| ROE | -31.1% | -70.5% |
| ROIC | — | -175.2% |
| 1y total return | +350.4% | -27.1% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: RLAY vs RXRX
| 지표 | RLAY | RXRX |
|---|---|---|
| 최종 가치 | $5.7K | $1.1K |
| 총수익률 | -43.2% | -89.2% |
| CAGR | -10.0% | -33.9% |
| 변동성 | 76.7% | 92.6% |
| 샤프 | 0.19 | -0.05 |
| 소르티노 | 0.29 | -0.08 |
| 최대 낙폭 | -94.7% | -93.1% |
공통 거래일 1352일 기준, 2021-04-16 → 2026-09-02 · 무위험수익률 3.92% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)